Corbus Pharmaceuticals Holdings Current Ratio Growth & History (CRBP)
Corbus Pharmaceuticals Holdings's current ratio was 8.07 for fiscal 2025.
View full Corbus Pharmaceuticals Holdings company overviewCorbus Pharmaceuticals Holdings annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 8.07 | −4.88 | −37.67% |
| 2024 | 2024-12-31 | 12.94 | 12.21 | +1653.36% |
| 2023 | 2023-12-31 | 0.74 | −4.02 | −84.49% |
| 2022 | 2022-12-31 | 4.76 | −1.13 | −19.19% |
| 2021 | 2021-12-31 | 5.89 | 3.01 | +104.11% |
| 2020 | 2020-12-31 | 2.89 | 1.79 | +163.94% |
| 2019 | 2019-12-31 | 1.09 | −1.35 | −55.28% |
| 2018 | 2018-12-31 | 2.45 | −5.54 | −69.37% |
| 2017 | 2017-12-31 | 7.98 | 6.03 | +308.23% |
| 2016 | 2016-12-31 | 1.96 | −1.55 | −44.17% |
| 2015 | 2015-12-31 | 3.50 | −5.35 | −60.43% |
| 2014 | 2014-12-31 | 8.85 | 8.38 | +1779.96% |
| 2013 | 2013-12-31 | 0.47 | — | — |
Corbus Pharmaceuticals Holdings quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.71 | −3.50 | −37.97% |
| Q1 2026 | 2026-03-31 | 7.92 | −3.91 | −33.04% |
| Q4 2025 | 2025-12-31 | 8.07 | −4.88 | −37.67% |
| Q3 2025 | 2025-09-30 | 6.31 | −7.53 | −54.44% |
| Q2 2025 | 2025-06-30 | 9.21 | 3.03 | +48.95% |
| Q1 2025 | 2025-03-31 | 11.82 | 7.13 | +151.81% |
| Q4 2024 | 2024-12-31 | 12.94 | 12.21 | +1653.36% |
| Q3 2024 | 2024-09-30 | 13.84 | 12.85 | +1298.92% |
| Q2 2024 | 2024-06-30 | 6.18 | 3.85 | +164.78% |
| Q1 2024 | 2024-03-31 | 4.69 | 1.50 | +46.97% |
| Q4 2023 | 2023-12-31 | 0.74 | −4.02 | −84.49% |
| Q3 2023 | 2023-09-30 | 0.99 | −2.87 | −74.34% |
| Q2 2023 | 2023-06-30 | 2.34 | −2.48 | −51.48% |
| Q1 2023 | 2023-03-31 | 3.19 | −2.66 | −45.42% |
| Q4 2022 | 2022-12-31 | 4.76 | −1.13 | −19.19% |
| Q3 2022 | 2022-09-30 | 3.86 | −2.66 | −40.81% |
| Q2 2022 | 2022-06-30 | 4.81 | −1.14 | −19.17% |
| Q1 2022 | 2022-03-31 | 5.85 | 0.33 | +6.03% |
| Q4 2021 | 2021-12-31 | 5.89 | 3.01 | +104.11% |
| Q3 2021 | 2021-09-30 | 6.51 | 4.45 | +215.95% |
| Q2 2021 | 2021-06-30 | 5.96 | 3.86 | +184.81% |
| Q1 2021 | 2021-03-31 | 5.52 | 3.94 | +249.92% |
| Q4 2020 | 2020-12-31 | 2.89 | 1.79 | +163.94% |
| Q3 2020 | 2020-09-30 | 2.06 | 0.18 | +9.47% |
| Q2 2020 | 2020-06-30 | 2.09 | −0.47 | −18.35% |
| Q1 2020 | 2020-03-31 | 1.58 | −0.21 | −11.57% |
| Q4 2019 | 2019-12-31 | 1.09 | −1.35 | −55.28% |
| Q3 2019 | 2019-09-30 | 1.88 | −1.57 | −45.46% |
| Q2 2019 | 2019-06-30 | 2.56 | −2.46 | −49.01% |
| Q1 2019 | 2019-03-31 | 1.78 | −5.46 | −75.39% |
| Q4 2018 | 2018-12-31 | 2.45 | −5.54 | −69.37% |
| Q3 2018 | 2018-09-30 | 3.45 | −2.55 | −42.45% |
| Q2 2018 | 2018-06-30 | 5.02 | −1.35 | −21.13% |
| Q1 2018 | 2018-03-31 | 7.25 | 0.04 | +0.53% |
| Q4 2017 | 2017-12-31 | 7.98 | 6.03 | +308.23% |
| Q3 2017 | 2017-09-30 | 6.00 | 3.01 | +100.62% |
| Q2 2017 | 2017-06-30 | 6.37 | 1.87 | +41.61% |
| Q1 2017 | 2017-03-31 | 7.21 | 4.72 | +189.20% |
| Q4 2016 | 2016-12-31 | 1.96 | −1.55 | −44.17% |
| Q3 2016 | 2016-09-30 | 2.99 | −4.08 | −57.72% |
| Q2 2016 | 2016-06-30 | 4.50 | 0.44 | +10.90% |
| Q1 2016 | 2016-03-31 | 2.49 | −6.85 | −73.31% |
| Q4 2015 | 2015-12-31 | 3.50 | −5.35 | −60.43% |
| Q3 2015 | 2015-09-30 | 7.07 | −5.24 | −42.55% |
| Q2 2015 | 2015-06-30 | 4.06 | — | — |
| Q1 2015 | 2015-03-31 | 9.34 | — | — |
| Q4 2014 | 2014-12-31 | 8.85 | 8.38 | +1779.96% |
| Q3 2014 | 2014-09-30 | 12.31 | — | — |
| Q4 2013 | 2013-12-31 | 0.47 | — | — |
Corbus Pharmaceuticals Holdings current ratio trends
Over the last five fiscal years, Corbus Pharmaceuticals Holdings's current ratio increased from 2.89 to 8.07, a change of 5.18. The latest reported quarter, Q2 2026, shows 5.71.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corbus Pharmaceuticals Holdings source filings ↗